2020
DOI: 10.1016/s1470-2045(20)30202-3
|View full text |Cite
|
Sign up to set email alerts
|

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
59
1
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 75 publications
(63 citation statements)
references
References 33 publications
2
59
1
1
Order By: Relevance
“…8 Cabozantinib may promote an immune-permissive environment that enhances response to ICIs. [17][18][19][20] In preclinical models, cabozantinib synergized with ICIs to inhibit tumor growth and mitigate immunosuppression 18 ; and in clinical studies, cabozantinib increased the numbers of tumorinfiltrating cytotoxic T cells and reduced immunosuppressive cells. 17,20 These studies provided the rationale to combine cabozantinib with immunotherapy.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…8 Cabozantinib may promote an immune-permissive environment that enhances response to ICIs. [17][18][19][20] In preclinical models, cabozantinib synergized with ICIs to inhibit tumor growth and mitigate immunosuppression 18 ; and in clinical studies, cabozantinib increased the numbers of tumorinfiltrating cytotoxic T cells and reduced immunosuppressive cells. 17,20 These studies provided the rationale to combine cabozantinib with immunotherapy.…”
Section: Introductionmentioning
confidence: 99%
“…[17][18][19][20] In preclinical models, cabozantinib synergized with ICIs to inhibit tumor growth and mitigate immunosuppression 18 ; and in clinical studies, cabozantinib increased the numbers of tumorinfiltrating cytotoxic T cells and reduced immunosuppressive cells. 17,20 These studies provided the rationale to combine cabozantinib with immunotherapy. 21 Recently, cabozantinib in combination with the programmed cell death protein-1 inhibitor nivolumab was approved as a firstline therapy for patients with advanced ccRCC based on outcomes from the phase III CheckMate 9ER study, which showed improved PFS, overall survival, and ORR with the combination therapy versus sunitinib.…”
Section: Introductionmentioning
confidence: 99%
“…13,14 Preclinical models have suggested that the MET pathway mediates resistance to VEGF-targeted therapy in several cancers, including RCC, 15,16 and multiple clinical trials investigating cabozantinib in GU tumors have shown clinical activity. [17][18][19] ICIs are now part of the standard of care for mUC and mRCC 7,10 and have been investigated in CRPC and metastatic germ cell tumors (mGCTs). 20,21 Nivolumab is a monoclonal antibody against the programmed cell death protein 1 (PD-1) cell surface membrane receptor.…”
Section: Introductionmentioning
confidence: 99%
“…In a phase II trial involving patients with metastatic UC refractory to platinum-based therapy, cabozantinib was well-tolerated and produced an ORR of 19%. Among 68 patients, the most common grade 3-4 AEs were fatigue [6(9%)], hypertension [5(7%)], proteinuria [4(6%)], and hypophosphatemia [4(6%)] ( 86 ).…”
Section: Future Perspectives For Bladder Cancer Treatmentmentioning
confidence: 99%